CoChat

Nationwide Surveillance of Azole Resistance in Aspergillus Diseases

Open access
Vermeulen, Edith, Maertens, Johan, De Bel, Annelies, Nulens, Eric, Boelens, Jerina, Surmont, Ignace, Mertens, Anna, Boel, An, Lagrou, Katrien · 2015 · Antimicrobial Agents and Chemotherapy
Cited by 92

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aspergillus disease affects a broad patient population, from patients with asthma to immunocompromised patients. Azole resistance has been increasingly reported in both clinical and environmental Aspergillus strains. The prevalence and clinical impact of azole resistance in different patient populations are currently unclear. This 1-year prospective multicenter cohort study aimed to provide detailed epidemiological data on Aspergillus resistance among patients with Aspergillus disease in Belgium. Isolates were prospectively collected in 18 hospitals (April 2011 to April 2012) for susceptibility testing. Clinical and treatment data were collected with a questionnaire. The outcome was evaluated to 1 year after a patient's inclusion. A total of 220 Aspergillus isolates from 182 patients were included. The underlying conditions included invasive aspergillosis ( n = 122 patients), allergic bronchopulmonary aspergillosis (APBA) ( n = 39 patients), chronic pulmonary aspergillosis ( n = 10 patients), Aspergillus bronchitis ( n = 7 patients), and aspergilloma ( n = 5 patients). The overall azole resistance prevalence was 5.5% (95% confidence interval [CI] 2.8 to 10.2%) and was 7.0% (4/57; 95% CI, 2.3 to 17.2%) in patients with APBA, bronchitis, aspergilloma, or chronic aspergillosis and 4.6% in patients with invasive aspergillosis (5/108; 95% CI, 1.7 to 10.7%). The 6-week survival in invasive aspergillosis was 52.5%, while susceptibility testing revealed azole resistance in only 2/58 of the deceased patients. The clinical impact of Aspergillus fumigatus resistance was limited in our patient population with Aspergillus diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.00233-15

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 92

Metadata

Authors
Vermeulen, E., Maertens, J., De Bel, A., Nulens, E., Boelens, J., Surmont, I., Mertens, A., Boel, A., & Lagrou, K.
Venue
Antimicrobial Agents and Chemotherapy
Published
2015-08
Volume
59
Issue
8
Pages
4569-4576
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W1937265692
Cited by
92
References
6
FWCI
8.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nationwide Surveillance of Azole Resistance in Aspergillus Diseases. https://app.cochat.ai/papers/10.1128/aac.00233-15
The paper
Vermeulen, E., Maertens, J., De Bel, A., Nulens, E., Boelens, J., Surmont, I., Mertens, A., Boel, A., & Lagrou, K. (2015). Nationwide Surveillance of Azole Resistance in Aspergillus Diseases. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00233-15

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.